This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kaiser, T. Articles by Sawicki, P. T Search for Related Content Social Bookmarking                         What's this?

Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy? A systematic review of randomised controlled trials

DIeM - Institute for Evidence Based Medicine, Cologne, Germany, t.kaiser{at}di-em.de, St. Franziskus Hospital, Cologne, Germany

Christiane Florack

DIeM - Institute for Evidence Based Medicine, Cologne, Germany

Uta Stephan

DIeM - Institute for Evidence Based Medicine, Cologne, Germany

Peter T Sawicki

DIeM - Institute for Evidence Based Medicine, Cologne, Germany, St. Franziskus Hospital, Cologne, Germany

Does antihypertensive treatment in normotensive patients with diabetic nephropathy alter the progression of kidney failure? We have evaluated studies of renal function which either assessed the effects of different therapeutic blood pressure (BP) goals, or the effects of antihypertensive therapy within the normotensive BP range. Need for renal replacement therapy was regarded as the most valid end point for assessment of deterioration of nephropathy, and change in the glomerular filtration rate (GFR) was regarded as a valid surrogate parameter. Five randomised controlled trials (RCTs) which included normotensive and hypertensive type 1 and type 2 diabetic patients have investigated the effect of lowering of BP within the normotensive range, or from hypertensive values to within the normotensive range. Albumin excretion in urine decreased in the groups randomised to lower BP values, but none of the trials demonstrated any beneficial effect of this intervention on the progression of kidney failure as assessed by the course of GFR. In conclusion, in diabetic patients with microalbuminuria or overt nephropathy, there is no evidence in the literature from RCTs for a beneficial effect of lowering BP within the normotensive range on the risk of kidney replacement therapy or on the loss of glomerular function.

Key Words: diabetic nephropathy • blood pressure • albuminuria • glomerular filtration rate • normotension • hypertension.

References

• Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Björck S., Mulec H., Johnsen SA, Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-42.[Web of Science][Medline] [Order article via Infotrieve]
• Bauer JH, Reams GP, Hewett J. et al. A randomised, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992;20:443-57.[Web of Science][Medline] [Order article via Infotrieve]
• Elving LD, Wetzels JMF, van Lier HJJ, de Nobel E., Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994;37:604-09.[Web of Science][Medline] [Order article via Infotrieve]
• Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994;3:292-300.[CrossRef][Medline] [Order article via Infotrieve]
• Rossing P., Tarnow L., Boelskifte S., Jensen BR, Nielsen FS, Parving HH Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997;46:481-7.[Abstract]
• Sawicki PT Stabilisation of glomerular filtration rate over two years in patients with diabetic nephropathy and intensified therapy regimes. Nephrol Dial Transplant 1997;12:1890-9.[Abstract/Free Full Text]
• Hovind P., Rossing P., Tarnow L., Smith UM, Parving HH Progression of diabetic nephropathy. Kidney Int 2001;59:702-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rossing P., Hougaard P., Parving HH Risk factors for development of incipient and overt nephropathy in Type 1 diabetic patients. Diabetes Care 2002;25:859-64.[Abstract/Free Full Text]
• American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002;25(Suppl 1):S85-S89.[CrossRef]
• Sign. Management of diabetic nephropathy. http://www.sign.ac.uk/guidelines/fulltext/55/section5.html (accessed 13 February 2003).
• Ramsay LE, Williams B., Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sawicki PT, Berger M. Measuring progression of diabetic nephropathy. Review. Eur J Clin Invest 1994;24:651-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003 ]. http://www.cochrane.de/cochrane/handbook/handbook.htm (accessed 13 February 2003).
• Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schrier RW, Estacio RO, Esler A., Mehler P. Effects of aggressive BP control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Estacio RO, Jeffers BW, Gifford N., Schrier RW Effect of BP control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.[Web of Science][Medline] [Order article via Infotrieve]
• Lewis JB, Berl T., Bain RP, Rohde RP, Lewis EJ Effect of intensive BP control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999;34:809-17.[Web of Science][Medline] [Order article via Infotrieve]
• Parving HH, Hommel E., Jensen BR, Hansen HP Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Viberti G., Mogensen CE, Groop LC, Pauls JF Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.[Abstract/Free Full Text]
• Parving HH, Hommel E., Damkjaer Nielsen M., Giese J. Effect of captopril on BP and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989;299:533-6.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 4, 278-281 (2003)
DOI: 10.1177/14746514030030040801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kaiser, T. Articles by Sawicki, P. T Search for Related Content Social Bookmarking                         What's this?